The microRNA expression changes associated with malignancy and SDHB mutation in pheochromocytoma

Endocrine-Related Cancer

Volumn 19, Issue 2, 2012, Pages 157-166

  Patterson, E ^a   Webb, R ^a   Weisbrod, A ^a   Bian, B ^a   He, M ^a   Zhang, L ^a   Holloway, A K ^b   Krishna, R ^a   Nilubol, N ^a   Pacak, K ^c   Kebebew, E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 101; MICRORNA 183; MICRORNA 483 5P; SUCCINATE DEHYDROGENASE; SUCCINATE DEHYDROGENASE SUBUNIT B; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; BENIGN TUMOR; CANCER CLASSIFICATION; DIAGNOSTIC ACCURACY; FEMALE; GENE EXPRESSION PROFILING; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MICROARRAY ANALYSIS; PHEOCHROMOCYTOMA; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS;

ADOLESCENT; ADRENAL GLAND NEOPLASMS; ADULT; AGED; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GERM-LINE MUTATION; HUMANS; MALE; MICRORNAS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHEOCHROMOCYTOMA; REAL-TIME POLYMERASE CHAIN REACTION; RNA, NEOPLASM; SUCCINATE DEHYDROGENASE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84860890934     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-11-0308     Document Type: Article

References (23)

1. Amar L, Baudin E, Burnichon N, Peyrard S, Silvera S, Bertherat J, Bertagna X, Schlumberger M, Jeunemaitre X, Gimenez-Roqueplo AP et al. 2007 Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. Journal of Clinical Endocrinology and Metabolism 92 3822-3828. (doi:10.1210/jc.2007-0709)
2. Benn DE, Gimenez-Roqueplo AP, Reilly JR, Bertherat J, Burgess J, Byth K, Croxson M, Dahia PL, Elston M, Gimm O et al. 2006 Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. Journal of Clinical Endocrinology and Metabolism 91 827-836. (doi:10.1210/jc.2005-1862)
3. Blank A, Schmitt AM, Korpershoek E, van Nederveen F, Rudolph T, Weber N, Strebel RT, de Krijger R, Komminoth P & Perren A 2010 SDHB loss predicts malignancy in pheochromocytomas/sympathethic paragangliomas, but not through hypoxia signalling. Endocrine- Related Cancer 17 919-928. (doi:10.1677/ERC-09- 0316)
4. Caramuta S, Ozata DM, Velazquez-Fernandez D, Akcakaya P, Xie H, Hoog A, Zedenius J, Backdahl M, Larsson C & Lui WO 2011 The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma. Endocrine- Related Cancer 18 643-655. (doi:10.1530/ERC-11-0082)
5. Comino-Mendez I, Gracia-Aznarez FJ, Schiavi F, Landa I, Leandro-Garcia LJ, Leton R, Honrado E, Ramos-Medina R, Caronia D, Pita G et al. 2011 Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nature Genetics 43 663-667. (doi:10.1038/ng.861)
6. Ferracin M, Veronese A & Negrini M 2010 Micromarkers: miRNAs in cancer diagnosis and prognosis. Expert Review of Molecular Diagnostics 10 297-308. (doi:10.1586/erm.10.11)
7. Gimenez-Roqueplo AP, Favier J, Rustin P, Rieubland C, Crespin M, Nau V, Khau Van Kien P, Corvol P, Plouin PF & Jeunemaitre X 2003 Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Research 63 5615-5621. (Pubitemid 37139886)
8. Grogan RH, Mitmaker EJ & Duh QY 2011 Changing paradigms in the treatment of malignant pheochromocytoma. Cancer Control 18 104-112.
9. Hannafon BN, Sebastiani P, de Las Morenas A, Lu J & Rosenberg CL 2011 Expression of microRNA and their gene targets are dysregulated in preinvasive breast cancer. Breast Cancer Research 13 R24. (doi:10.1186/bcr2839)
10. Meyer-Rochow GY, Jackson NE, Conaglen JV, Whittle DE, Kunnimalaiyaan M, Chen H, Westin G, Sandgren J, Stalberg P, Khanafshar E et al. 2010 MicroRNA profiling of benign and malignant pheochromocytomas identifies novel diagnostic and therapeutic targets. Endocrine- Related Cancer 17 835-846. (doi:10.1677/ERC-10-0142)
11. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A et al. 2008 Circulating microRNAs as stable blood-based markers for cancer detection. PNAS 105 10513-10518. (doi:10.1073/pnas.0804549105)
12. Neumann HP, Sullivan M, Winter A, Malinoc A, Hoffmann MM, Boedeker CC, Bertz H, Walz MK, Moeller LC, Schmid KW et al. 2011 Germline mutations of the TMEM127 gene in patients with paraganglioma of head and neck and extraadrenal abdominal sites. Journal of Clinical Endocrinology and Metabolism 96 E1279-E1282. (doi:10.1210/jc.2011-0114)
13. Patterson EE, Holloway AK, Weng J, Fojo T & Kebebew E 2011 MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy. Cancer 117 1630-1639. (doi:10.1002/cncr.25724)
14. Plouin PF, Amar L & Lepoutre C 2010 Phaeochromocytomas and functional paragangliomas: clinical management. Best Practice & Research. Clinical Endocrinology & Metabolism 24 933-941. (doi:10.1016/j.beem.2010.10.002)
15. Qin Y, Yao L, King EE, Buddavarapu K, Lenci RE, Chocron ES, Lechleiter JD, Sass M, Aronin N, Schiavi F et al. 2010 Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nature Genetics 42 229-233. (doi:10.1038/ng.533)
16. Sarver AL, Li L & Subramanian S 2010 MicroRNA miR-183 functions as an oncogene by targeting the transcription factor EGR1 and promoting tumor cell migration. Cancer Research 70 9570-9580. (doi:10.1158/0008-5472.CAN-10-2074)
17. Smyth GK 2004 Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Statistical Applications in Genetics and Molecular Biology 3 (Article 3) 1-26. (doi:10.2202/1544-6115.1027)
18. Smyth GK, Michaud J & Scott HS 2005 Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics 21 2067-2075. (doi:10.1093/bioinformatics/bti270)
19. Timmers HJ, Gimenez-Roqueplo AP, Mannelli M & Pacak K 2009 Clinical aspects of SDHx-related pheochromocytoma and paraganglioma. Endocrine-Related Cancer 16 391-400. (doi:10.1677/ERC-08-0284)
20. Tombol Z, Eder K, Kovacs A, Szabo PM, Kulka J, Liko I, Zalatnai A, Racz G, Toth M, Patocs A et al. 2010 MicroRNA expression profiling in benign (sporadic and hereditary) and recurring adrenal pheochromocytomas. Modern Pathology 23 1583-1595. (doi:10.1038/modpathol.2010.164)
21. Yang YH, Dudoit S, Luu P, Lin DM, Peng V, Ngai J & Speed TP 2002 Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Research 30 e15. (doi:10.1093/nar/30.4.e15)
22. Yao L, Schiavi F, Cascon A, Qin Y, Inglada-Perez L, King EE, Toledo RA, Ercolino T, Rapizzi E, Ricketts CJ et al. 2010 Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomas. Journal of the American Medical Association 304 2611-2619. (doi:10.1001/jama.2010.1830)
23. Zarnegar R, Kebebew E, Duh QY & Clark OH 2006 Malignant pheochromocytoma. Surgical Oncology Clinics of North America 15 555-571. (doi:10.1016/j.soc.2006.05.009)